GSA Capital Partners LLP bought a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 29,513 shares of the company's stock, valued at approximately $849,000.
Other large investors have also recently added to or reduced their stakes in the company. CWM LLC acquired a new stake in shares of Verona Pharma in the second quarter worth $29,000. EMC Capital Management bought a new position in Verona Pharma in the 2nd quarter worth $38,000. GAMMA Investing LLC lifted its position in Verona Pharma by 70.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,336 shares of the company's stock worth $38,000 after acquiring an additional 553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Verona Pharma by 25.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company's stock valued at $75,000 after acquiring an additional 529 shares during the period. Finally, Legato Capital Management LLC acquired a new stake in shares of Verona Pharma in the second quarter valued at about $154,000. Institutional investors own 85.88% of the company's stock.
Insiders Place Their Bets
In other Verona Pharma news, CEO David Zaccardelli sold 245,784 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $4.38, for a total transaction of $1,076,533.92. Following the completion of the transaction, the chief executive officer now directly owns 15,004,920 shares in the company, valued at $65,721,549.60. This represents a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David R. Ebsworth bought 39,360 shares of Verona Pharma stock in a transaction dated Wednesday, November 6th. The stock was purchased at an average price of $4.80 per share, for a total transaction of $188,928.00. Following the purchase, the director now directly owns 920,003 shares in the company, valued at $4,416,014.40. This represents a 4.47 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 1,141,944 shares of company stock worth $5,004,952 over the last quarter. Company insiders own 4.80% of the company's stock.
Verona Pharma Stock Up 0.8 %
Shares of NASDAQ VRNA opened at $35.66 on Friday. Verona Pharma plc has a one year low of $11.39 and a one year high of $40.13. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The business has a fifty day simple moving average of $32.77 and a 200 day simple moving average of $23.62.
Verona Pharma (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12). The firm had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same period last year, the company posted ($0.18) EPS. As a group, equities research analysts expect that Verona Pharma plc will post -2.11 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research firms recently weighed in on VRNA. HC Wainwright boosted their price objective on Verona Pharma from $36.00 to $42.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Truist Financial upped their price target on Verona Pharma from $38.00 to $44.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. Canaccord Genuity Group raised their price objective on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company upped their target price on shares of Verona Pharma from $50.00 to $64.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Verona Pharma presently has a consensus rating of "Buy" and an average target price of $43.83.
Get Our Latest Analysis on VRNA
Verona Pharma Profile
(
Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
